RAA TE, Doreen G., Jitka MALČÍKOVÁ, Marek MRÁZ, Martin TRBUŠEK, M. Le GARFF-TAVERNIER, H. MERLE-BERAL, R. GREIL, O. MERKEL, Šárka POSPÍŠILOVÁ, K. LIN, A. R. PETTITT, T. STANKOVIC, A.R. OERS VAN, M.H. ELDERING, S. STILGENBAUER, T. ZENZ and A.P. KATER. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. British journal of haematology. England: Wiley-Blackwell, 2014, vol. 167, No 4, p. 565-569. ISSN 0007-1048. doi:10.1111/bjh.13006.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach
Authors RAA TE, Doreen G. (528 Netherlands), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Marek MRÁZ (203 Czech Republic, belonging to the institution), Martin TRBUŠEK (203 Czech Republic, belonging to the institution), M. Le GARFF-TAVERNIER (250 France), H. MERLE-BERAL (250 France), R. GREIL (40 Austria), O. MERKEL (40 Austria), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), K. LIN (826 United Kingdom of Great Britain and Northern Ireland), A. R. PETTITT (826 United Kingdom of Great Britain and Northern Ireland), T. STANKOVIC (826 United Kingdom of Great Britain and Northern Ireland), A.R. OERS VAN (528 Netherlands), M.H. ELDERING (528 Netherlands), S. STILGENBAUER (276 Germany), T. ZENZ (276 Germany) and A.P. KATER (528 Netherlands).
Edition British journal of haematology, England, Wiley-Blackwell, 2014, 0007-1048.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 4.971
RIV identification code RIV/00216224:14740/14:00078310
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1111/bjh.13006
UT WoS 000344351200017
Keywords in English chronic lymphocytic leukaemia; TP53 function assays; TP53 axis; TP53; ATM
Tags EL OK, kontrola MP, MP, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Martina Prášilová, učo 342282. Changed: 9. 2. 2015 12:35.
Chronic lymphocytic leukaemia (CLL) is characterized by an extremely variable clinical course, in which deletions of TP53 and ATM , regulators of the DNA-damage response (DDR-) pathway, are powerful predictors for adverse outcome and response to chemotherapy (Dohner et al , 2000). Deletions of chromosome 17p ( TP53 ) and 11q ( ATM ) coincide with TP53 and ATM mutations respectively, however with mark- edly different frequencies (80% and 40% respectively; Mal- cikova et al , 2009; Navrkalova et al , 2013). Sole TP53 mutations and deletions usually lead to TP53 (p53) dysfunc- tion (Mohr et al , 2011) and, in case of deletions in ATM ,a mutation of the residual ATM allele determines whether there is complete ATM inactivation resulting in TP53-dys- function (Navrkalova et al , 2013). Therefore, analysis of mutations in TP53 and ATM genes in addition to fluorescent in situ hybridization (FISH) analysis is of additional clinical value (Skowronska et al , 2012). However, mutational analysis of TP53 and ATM is currently not standardized and is chal- lenging, especially for ATM due to extreme gene size with lack of well-characterized mutations (Navrkalova et al , 2013)
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
NT13493, research and development projectName: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
NT13519, research and development projectName: Časná identifikace CLL pacientů s dosud nevyselektovanými mutacemi v proteinu p53
4SGA8684, interní kód MUName: The role of microRNAs in the biology of B cell leukemias and lymphomas (Acronym: miRNA in CLL)
Investor: South-Moravian Region
PrintDisplayed: 27. 5. 2022 06:17